Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Xencor Catalyst Calendar
Proactively evaluate Xencor Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Xencor Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 31 Dec 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 30 Jun 2020 | Phase I Trial Results | ICON Plc; Xencor Inc | ICLR; XNCR | tidutamab | Oncology | Gastrointestinal Stromal Tumor (GIST); Gastrointestinal Tumor; Lung Cancer; Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET); Neuroendocrine Tumors; Pancreatic Cancer; Solid Tumor | Company Press Release |
| 31 Dec 2019 | IND Filing (US) | Xencor Inc | XNCR | XmAb-306 | Oncology | - | Company Press Release |
| 31 Dec 2019 | Phase I Trial Results | ICON Plc; Xencor Inc | ICLR; XNCR | plamotamab | Hematological Disorders; Oncology | B-Cell Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma; Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma); Follicular Lymphoma; Hematological Tumor; Lymphoma; Mantle Cell Lymphoma; Nodal Marginal Zone B-Cell Lymphoma; Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Splenic Marginal Zone B-Cell Lymphoma; Unspecified B-Cell Lymphomas; Unspecified Hematological Disorders; Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) | Company Presentation |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer